Search
Regulatory Story
Company GlaxoSmithKline PLC
TIDM GSK
Headline Director/PDMR Shareholding
Released 17:37 04-Sep-2019
Number 2654L17

RNS Number : 2654L
GlaxoSmithKline PLC
04 September 2019
 

GlaxoSmithKline plc (the 'Company' and 'GSK')

Awards under the GSK Deferred Investment Award programme

In accordance with the requirements of the EU Market Abuse Regulation the Company today announces a change in the interests of Persons Discharging Managerial Responsibilities ('PDMR') in notional shares of the Company as a result of awards made under the GlaxoSmithKline Deferred Investment Award programme (the 'Programme') on 3 September 2019. The awards under the Programme will vest on 13 February 2022.

Awards are made over notional Ordinary Shares. Vesting is subject to the individuals not having served GSK notice or having been terminated by GSK for cause. The awards will not accrue dividends, and on vesting, will be paid in cash.  Executive Directors are not eligible to receive awards under the Programme.  

Both awards relate to the PDMRs' employment prior to their being appointed to GSK's Corporate Executive Team.
 

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms D Conrad

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

An award of notional Ordinary Shares under the Company's Deferred Investment Award programme.

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£17.434

10,050

 

 

 

 

 

d)

Aggregated information

 

N/A (single transaction)

Aggregated volume Price

 

e)

Date of the transaction

2019-09-03

f)

Place of the transaction

 

N/A

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms S Jackson

b)

Position/status

SVP, Global Communication and CEO Office

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

An award of notional Ordinary Shares under the Company's Deferred Investment Award programme.  

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£17.434

10,050

 

 

 

 

 

d)

Aggregated information

 

N/A (single transaction)

Aggregated volume Price

 

e)

Date of the transaction

2019-09-03

f)

Place of the transaction

 

N/A

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHQZLFBKKFXBBE
London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.